The relationship between hypoprolactinemia and cardiometabolic health in women
Authors' conclusion
Our data suggests that a serum PRL level lower than 3 ng/mL could be adopted for identifying PRL-associated cardiometabolic disease in both sexes.
Study context
- Population
- Women aged 20–81 year from SHIP-START (Germany, discovery cohort) and women aged 33–37 year from WENDY (Finland, validation cohort)2,048 SHIP-START
- Exposure
- Low vs normal serum prolactin (PRL)
- Outcome
- Lower reference limit for PRL in women (2.5% of the log10 PRL distribution)
Methodological detailsdiscovery and validation cohorts
- Discovery and validation cohorts
Main finding
As reported in the abstract
Low serum PRL threshold
Premenopausal women, SHIP-START
2.60 ng/mL
Women of all ages, SHIP-START
2.29 ng/mL
WENDY
4.84 ng/mL
Observational data: associations, not effects.
Further findings
| Outcome | Estimate | |
|---|---|---|
| Incident MI, SHIP-START · median 12 year follow-up (IQR = 6.9-15.8 year)PRL < 2.30 ng/mLvs PRL 5.0-34.9 ng/mL | aHR 4.19 (95% CI 1.74–10.12) | |
| Incident MI, SHIP-START · median 12 year follow-up (IQR = 6.9-15.8 year)PRL < 3 ng/mLvs PRL 5.0-34.9 ng/mL | HR 2.74 (95% CI 1.44–5.21) | |
| 0.050.21520Ratio (log scale) |
T2D and metabolic syndrome at baseline, SHIP-START
- Lower PRL more commonly associated with T2D and metabolic syndrome vs PRL 5.0-34.9 ng/mL
Original publication
The relationship between hypoprolactinemia and cardiometabolic health in women. Eur J Endocrinol. Published 12 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →